A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects

Phase 1 Completed 30 enrolled Taisho Pharmaceutical Co., Ltd.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open-label, single-center, single-sequence study to evaluate the drug-drud interaction between the CYP3A substrate triazolam and TS-172 (part A) and the potent CYP3A inhibitor itraconazole and TS-172 (part B) in healthy male subjects on their pharmacokinetics, safety and tolerability

Timeline

Start: 2025-03-11
Primary completion: 2025-04-30
Completion: 2025-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Itraconazole	Small molecule	200 mg	Oral
Subject	TS-172	Unknown	20 mg	Oral
Subject	Triazolam	Small molecule	0.25 mg	Oral

Indications

No indication recorded.